Isolated Intraparotid Kaposi Sarcoma in Human Immunodeficiency Virus Type 1 Infection

Rizos, Evangelos; Drosos, Alexandros A.; Ioannidis, John P.A.
December 2003
Mayo Clinic Proceedings;Dec2003, Vol. 78 Issue 12, p1561
Academic Journal
Isolated Kaposi sarcoma (KS) of the parotid gland is an uncommon hut distinct entity in patients with human immunodeficiency virus type 1 (HIV-1). A 30-year-old white homosexual man in whom HIV-1 had been diagnosed 2 years previously developed right parotid gland enlargement in the absence of constitutional symptoms. He had been taking zidovudine, lamivudine, and indinavir; his CD4 cell count was 0.297 × 10[sup 9]/L, and HIV-1 RNA load was 47 copies/mL. After surgical excision of the parotid gland, biopsy findings disclosed KS of an intraparotid lymph node. A literature review revealed 6 other men with HIV-1 and isolated parotid KS. To our knowledge, our patient is the first to have received triple antiretroviral therapy with excellent immunological and virological response and parotid gland enlargement that might reflect immune reconstitution. Even in the absence of skin or other lesions, KS should be considered in the differential diagnosis of parotid gland enlargement in patients with HIV-1, even in those who are responding to highly active antiretroviral treatment.


Related Articles

  • Photo Quiz. Facial Masses.  // American Family Physician;10/1/2000, Vol. 62 Issue 7, p1619 

    Discusses benign lymphoepithelial cystic lesions of the parotid glands in a patient with human immunodeficiency virus. Symptoms of bilateral parotid enlargement; Suggestion if the diagnosis is uncertain.

  • Parotid gland lymphoepithelial cysts in HIV infection. Rojas, Rafael; Di Leo, Jane; Palacios, Enrique; Rojas, Isabel; Restrepo, Santiago // ENT: Ear, Nose & Throat Journal;Jan2003, Vol. 82 Issue 1, p20 

    Presents the case of an HIV-positive patient with parotid gland lymphoepithelial cysts. Symptoms of the disease; Findings of the computed tomography; Development of the cysts in the early stages of HIV infection.

  • Here's how maraviroc and other entry inhibitors work.  // AIDS Alert;Aug2007, Vol. 22 Issue 8, p89 

    The article focuses on how current entry inhibitors, including the antiretroviral maraviroc, target one of the three stages of the entry of HIV into cells according to doctor W. David Hardy of the Cedars-Sinai Medical Center in Los Angeles, California.

  • A third of those in need of antiretrovirals in poor countries can now get them. Zarocostas, John // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/2/2010, Vol. 341 Issue 7775, p695 

    The article focuses on the findings of the global report "Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector--Progress Report 2010," giving particular emphasis on helping people to have access to antiretrovirals.

  • Intrauterine, postnatal growth unaffected by exposure to HIV, antenatal antiretrovirals.  // Infectious Disease News;Feb2014, Vol. 27 Issue 2, p26 

    The article discusses research into the effects of exposure to HIV and antenatal antiretrovirals on infants' intrauterine or early postnatal growth and references a study by J. Jao and colleagues published in a 2014 issue "The Pediatric Infectious Disease Journal."

  • Highly efficient neutralization of human immunodeficiency viruses by plasma from antiretroviral drug treated patients is mediated by IgG fractions. Andrabi, R.; Makhdoomi, M.; Kumar, R.; Bala, M.; Velpandian, T.; Luthra, K. // Retrovirology;2012 Supplement, Vol. 9 Issue Suppl 2, p1 

    An abstract of the conference paper "Highly Efficient Neutralization of Human Immunodeficiency Viruses by Plasma From Antiretroviral Drug Treated Patients Is Mediated by IgG Fractions," by R. Andrabi and colleagues is presented.

  • Is It Time to Treat HIV Elite Controllers with Combined Antiretroviral Therapy? Torre, Donato // Clinical Infectious Diseases;5/15/2010, Vol. 50 Issue 10, p1425 

    A letter to the editor is presented in response to the article related to treatment HIV of with combination antiretroviral therapy (cART) that was published in a previous issue of the periodical is presented.

  • Reply to Torre. Sedaghat, Ahmad R.; Rastegar, Darius A.; O'Connell, Karen A.; Dinoso, Jason B.; Wilke, Claus O.; Blankson, Joel N. // Clinical Infectious Diseases;5/15/2010, Vol. 50 Issue 10, p1425 

    A letter to the editor is presented offering information related to combination antiretroviral therapy (cART) for treating HIV.

  • Trapped in darkness. McPhee, A.T. // Current Science;9/19/97, Vol. 83 Issue 2, p10 

    Presents information on xeroderma pigmentosum (XP), a rare skin disease in which the body cannot repair skin damage caused by ultraviolet light. What dermatologist revealed about the skin disease; Number of persons with XP that develop skin cancer; Outline of some of the precautions that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics